TEL AVIV, Israel, March 21, 2017 /PRNewswire/ --
Steep Hill Labs, Inc., the world's leading cannabis science and technology company with significant footprints in lab testing, research and development, licensing, genetics, and remote testing has entered a joint venture with iCAN:Israel-Cannabis to leverage Steep Hill's science, IP, methodology, global collaboration and brand. The announcement was made at CannaTech, Israel's premier medical cannabis conference.
Steep Hill is one of a handful of leading cannabis genetic research labs with the ability to assist growers with marker assisted breeding. In partnership with iCAN, they will open an analytical, genetic, and R&D lab in Israel to further research the cannabis plant.
Cannabis data analysis will take the medicinal cannabis industry to the next level. Steep Hill Israel will empower growers with the technology to breed specific strains, based on genetics and expected chemical profiles for specific patient conditions/diseases. Steep Hill's collaborative research will provide the knowledge about the cannabis plant and its active compounds to be fully understood, and no longer demonized and misunderstood. Furthermore, DNA based testing; can be used not only for genetic analysis and strain identification, but also for safety and quality assurance.
"We believe that Israel is the epicenter of cannabis research and development. We look forward to its role in leading the evolution of medical cannabis worldwide," said Jmichaele Keller, CEO of Steep Hill Labs.
"iCAN is excited by its partnership with Steep Hill Labs because it gives us a technological advantage over everyone else in the industry. Steep Hill is the leading analytical lab in the United States, setting the standards for the industry. We see cannabis analysis as an enormous gateway to big data and machine learning algorithms which we can turn into commercialized global products set at Israeli standards."
Simultaneous to this announcement, Steep Hill is announcing Xcerpa(TM), a game-changing technology that facilitates the legal, global transport and long term storage of cannabis DNA. Steep Hill has exclusive global rights to the technology which impregnates a card with a DNA sample, allowing Steep Hill Israel to work on DNA and tie in genetic research around the globe.
About Steep Hill
Steep Hill Labs, Inc. is the world's leading cannabis science and technology company with significant footprints in lab testing, research and development, licensing, genetics and remote testing. Steep Hill's foundation is built on testing and analyzing medical and recreational marijuana to ensure compliance with public safety standards. In 2008, Steep Hill opened the first commercial cannabis lab in the United States and has been on the cutting edge since its inception. Steep Hill consists of four intersecting and highly complementary business units. 1) Lab Testing and R&D; 2) Licensing; 3) Steep Hill Express and Remote Testing; and 4) Genetics. No other company brings all four quadrants into one highly synergistic whole. Steep Hill was recently named by Wealth Daily as one of the top 5 Legal Cannabis Companies to Watch in 2017.
iCAN is a Global Accelerator of the Israeli Medical Cannabis Industry. iCAN identifies innovative ventures; invests; connects professionals from various industries; and serves as a hub of knowledge, awareness and education regarding Israeli Canna-Tech for audiences worldwide.
Contact Laura Kam, firstname.lastname@example.org , +972-54-806-8613.
SOURCE iCAN Israel-Cannabis and Steep Hill Labs, Inc.